Gyre Therapeutics acquires Cullgen

Gyre Therapeutics, a biotech firm listed on NASDAQ, announced it will acquire Cullgen in an all-stock transaction valued at approximately $300 million. This strategic move will transform Cullgen into a wholly-owned subsidiary of Gyre, expanding its portfolio with Cullgen’s targeted protein degradation technology and clinical programs. The merger is set to conclude in the early part of the second quarter of 2026, pending customary regulatory and shareholder approvals.

The acquisition will be funded through the issuance of new Series B Convertible Preferred Stock by Gyre. Each preferred share becomes convertible into five common shares upon stockholder approval of a Conversion Proposal, though this is limited to no more than 19.99% of Gyre’s pre-vote common stock and voting power. Existing Cullgen equity holders and those with in-the-money options will convert to Gyre equity under this deal’s structure. Also notable is the inclusion of a registration rights agreement requiring Gyre to file for a resale registration statement shortly after the deal closes.

The integration of Cullgen enhances Gyre by adding a robust targeted protein degradation and degrader antibody conjugate platform. Cullgen’s programs, which span pain management, solid tumors, and blood cancers, dovetail with Gyre’s existing capabilities, broadening the biopharma entity’s footprint across the U.S. and China. Importantly, this transaction will also result in a leadership change—Cullgen’s CEO, Ying Luo, will take over as Gyre's CEO, President, and a director, marking a significant shift in the company's management.

In the context of biotechnology M&A, this acquisition exemplifies the ongoing trend of consolidation as companies seek to bolster their capabilities and expand pipelines in highly competitive markets. The addition of Cullgen’s novel technologies is anticipated to position Gyre more favorably against competitors in the fields of protein degradation and oncology. The sector is witnessing an increased focus on combining diverse biotech platforms to enhance drug discovery and development synergy.

The completion of this transaction will hinge on Cullgen's shareholder approval and compliance with U.S. antitrust regulations under the Hart-Scott-Rodino Act. If these requirements are met, Gyre anticipates leveraging its enhanced platform to drive future growth and establish a more integrated biopharma presence in key markets. As the company navigates this acquisition, investors and analysts will be watching the integration process and potential regulatory impacts closely.